Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.

IO Biotech, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

ANNOUNCED CLINICAL IMPROVEMENT IN PROGRESSION FREE SURVIVAL OBSERVED IN PIVOTAL PHASE 3 TRIAL OF CYLEMBIO PLUS KEYTRUDA (PEMBROLIZUMAB) FOR THE TREATMENT OF FIRST-LINE ADVANCED MELANOMA, BUT STATISTICAL SIGNIFICANCE NARROWLY MISSED; COMPANY PLANS TO MEET WITH FDA THIS FALL TO DISCUSS DATA AND NEXT STEPS FOR A POTENTIAL REGULATORY SUBMISSION ENDED SECOND QUARTER WITH APPROXIMATELY $28.1 MILLION IN CASH AND CASH EQUIVALENTS; THE COMPANY EXPECTS THAT OUR CASH POSITION, TOGETHER WITH 12.5 MILLION IN PROCEEDS FROM THE SECOND TRANCHE OF THE EUROPEAN INVESTMENT BANK (EIB) LOAN FACILITY RECEIVED ON JULY 4, 2025, WILL BE SUFFICIENT TO CONTINUE FUNDING OUR OPERATIONS INTO THE FIRST QUARTER OF 2026 CORPORATE PRESENTATIONS ARE PLANNED FOR THE MORGAN STANLEY 23RD ANNUAL GLOBAL HEALTHCARE CONFERENCE ON SEPTEMBER 9, 2025, AND THE H.C. WAINWRIGHT 27TH ANNUAL GLOBAL INVESTMENT CONFERENCE ON SEPTEMBER 10, 2025 NEW YORK, AUG. 14, 2025 (GLOBE NEWSWIRE) -- IO BIOTECH (NASDAQ: IOBT), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL, IMMUNE-MODULATORY, OFF-THE-SHELF THERAPEUTIC CANCER VACCINES, TODAY REPORTED FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS FOR THE SECOND QUARTER OF 2025.

IO BIOTECH REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS HIGHLIGHTS

PATIENTS TREATED WITH CYLEMBIO (IMSAPEPIMUT AND ETIMUPEPIMUT, ADJUVANTED) PLUS PEMBROLIZUMAB ACHIEVED IMPROVEMENT IN PROGRESSION FREE SURVIVAL (PFS) COMPARED TO PATIENTS TREATED WITH PEMBROLIZUMAB MONOTHERAPY, HR=0.77 (CI 0.58-1.00), (P=0.056), WITH MEDIAN PFS (MPFS) OF 19.4 MONTHS VS. 11.0 MONTHS, RESPECTIVELY; THE RESULTS ON THE PRIMARY ENDPOINT NARROWLY MISSED THE STUDY'S STATISTICAL SIGNIFICANCE THRESHOLD OF P0.045 IN PATIENTS ENROLLED IN THIS STUDY WITHOUT PRIOR NEO-ADJUVANT/ADJUVANT ANTI-PD-1 TREATMENT (N=371), PATIENTS TREATED WITH CYLEMBIO PLUS PEMBROLIZUMAB ACHIEVED IMPROVEMENT IN PFS, HR: 0.74 (CI 0.56-0.98) (NOMINAL P=0.037), WITH MPFS OF 24.8 MONTHS VS.

IO BIOTECH ANNOUNCES CLINICAL IMPROVEMENT IN PROGRESSION FREE SURVIVAL DEMONSTRATED IN PIVOTAL PHASE 3 TRIAL OF CYLEMBIO PLUS KEYTRUDA (PEMBROLIZUMAB) FOR THE TREATMENT OF FIRST-LINE ADVANCED MELANOMA, BUT STATISTICAL SIGNIFICANCE NARROWLY MISSED

NEW YORK, AUG. 10, 2025 (GLOBE NEWSWIRE) -- IO BIOTECH (NASDAQ: IOBT), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY, TODAY ANNOUNCED THE COMPANY WILL HOLD A CONFERENCE CALL AND WEBCAST ON MONDAY, AUGUST 11, 2025, AT 8:30 AM ET TO DISCLOSE THE TOPLINE RESULTS OF THE PIVOTAL PHASE 3 TRIAL (IOB-013/KN-D18; NCT05155254) OF ITS INVESTIGATIONAL, IMMUNE-MODULATORY, OFF-THE-SHELF THERAPEUTIC CANCER VACCINE, CYLEMBIO (IMSAPEPIMUT AND ETIMUPEPIMUT, ADJUVANT) IN COMBINATION WITH PEMBROLIZUMAB VS. PEMBROLIZUMAB ALONE AS A FIRST-LINE TREATMENT FOR UNRESECTABLE OR METASTATIC (ADVANCED) MELANOMA.

IO BIOTECH TO ANNOUNCE TOPLINE RESULTS OF PIVOTAL PHASE 3 TRIAL OF CYLEMBIO IN COMBINATION WITH KEYTRUDA (PEMBROLIZUMAB) AS A FIRST-LINE TREATMENT FOR PATIENTS WITH ADVANCED MELANOMA

NEW YORK, MAY 20, 2025 (GLOBE NEWSWIRE) -- IO BIOTECH (NASDAQ: IOBT), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL, IMMUNE-MODULATORY, OFF-THE-SHELF THERAPEUTIC CANCER VACCINES, ANNOUNCED TODAY THAT MAI-BRITT ZOCCA, PHD, THE COMPANY'S PRESIDENT AND CEO, ALONG WITH AMY SULLIVAN, THE COMPANY'S CFO, AND QASIM AHMAD, MD, THE COMPANY'S CMO, WILL BE PARTICIPATING IN A FIRESIDE CHAT AT THE TD COWEN 6TH ANNUAL ONCOLOGY SUMMIT: INSIGHTS FOR ASCO & EHA BEING HELD VIRTUALLY MAY 27-28, 2025. ADDITIONALLY, DR. ZOCCA WILL BE PRESENTING AND DR. ZOCCA, AMY SULLIVAN, AND DR. AHMAD WILL BE PARTICIPATING IN ONE-ON-ONE INVESTOR MEETINGS AT THE JEFFERIES GLOBAL HEALTHCARE CONFERENCE TO BE HELD JUNE 3-5, 2025 IN NEW YORK, NY.

IO BIOTECH ANNOUNCES PARTICIPATION IN COWEN 6TH ANNUAL ONCOLOGY INNOVATION SUMMIT AND JEFFERIES GLOBAL HEALTHCARE CONFERENCE

PRIMARY ENDPOINT OF PIVOTAL PHASE 3 TRIAL (IOB-013/KN-D18) OF LEAD INVESTIGATIONAL THERAPEUTIC CANCER VACCINE IN PATIENTS WITH ADVANCED MELANOMA STILL EXPECTED TO READOUT IN THIRD QUARTER OF 2025 DATA PRESENTED AT RECENT CONGRESSES REINFORCES THE POTENTIAL OF THE COMPANY'S T-WIN CANDIDATES TO RESHAPE THE TUMOR MICROENVIRONMENT AND DRIVE MORE EFFECTIVE ANTI-TUMOR RESPONSES COMPANY RECOGNIZED AS ONE OF THE MOST INNOVATIVE BIOTECHNOLOGY COMPANIES IN THE WORLD BY FAST COMPANY COMPANY TO PARTICIPATE IN TD COWEN'S 6TH ANNUAL ONCOLOGY INNOVATION SUMMIT ON MAY 27 AND JEFFERIES GLOBAL HEALTHCARE CONFERENCE ON JUNE 4, 2025 NEW YORK, MAY 14, 2025 (GLOBE NEWSWIRE) -- IO BIOTECH (NASDAQ: IOBT), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL, IMMUNE-MODULATORY, OFF-THE-SHELF THERAPEUTIC CANCER VACCINES, TODAY REPORTED FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS FOR THE FIRST QUARTER OF 2025. THE COMPANY CONTINUES TO ADVANCE ITS PIPELINE, PRESENTING NEW DATA FURTHER DEFINING THE MECHANISM OF ACTION FOR ITS T-WIN THERAPEUTIC CANCER VACCINES, AND REAFFIRMING ITS EXPECTATION THAT THE PHASE 3 PIVOTAL TRIAL WILL READOUT IN THE THIRD QUARTER OF 2025.

IO BIOTECH REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS

NEW YORK, APRIL 26, 2025 (GLOBE NEWSWIRE) -- IO BIOTECH (NASDAQ: IOBT), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL, IMMUNE-MODULATORY, OFF-THE-SHELF THERAPEUTIC CANCER VACCINES, TODAY ANNOUNCED THAT ONE OF ITS SCIENTIFIC CO-FOUNDERS, MADS HALD ANDERSEN, DMSC, PHD, DIRECTOR OF THE NATIONAL CENTER FOR CANCER IMMUNE THERAPY (CCIT-DK), CHAIRED AND PRESENTED AT AN EDUCATIONAL SESSION ON CANCER VACCINES AT THE 2025 AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) ANNUAL MEETING. THE SESSION BROUGHT TOGETHER LEADING ONCOLOGY SCIENTISTS AND EXPLORED THE LATEST ADVANCEMENTS IN CANCER VACCINE RESEARCH, FROM PRECLINICAL INNOVATION TO CLINICAL IMPLEMENTATION, PROVIDING PERSPECTIVE ON THE FUTURE OF CANCER VACCINES AND THEIR POTENTIAL TO RESHAPE CANCER IMMUNOTHERAPY (SESSION #ED59).

IO BIOTECH SHOWCASES SCIENTIFIC LEADERSHIP THROUGH CANCER VACCINES EDUCATIONAL SESSION AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) ANNUAL MEETING 2025

PRECLINICAL DATA FURTHER SUPPORT THE POTENTIAL OF DUAL-ANTIGEN AND TGF--DIRECTED VACCINES TO RESHAPE THE TUMOR MICROENVIRONMENT AND DRIVE ANTI-TUMOR IMMUNITY NEW YORK, APRIL 25, 2025 (GLOBE NEWSWIRE) -- IO BIOTECH (NASDAQ: IOBT), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL, IMMUNE-MODULATORY, OFF-THE-SHELF THERAPEUTIC CANCER VACCINES, TODAY ANNOUNCED THE PRESENTATION OF NEW PRECLINICAL DATA FOR TWO VACCINE CANDIDATES DEVELOPED BASED ON ITS T-WIN PLATFORM AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) ANNUAL MEETING 2025 IN CHICAGO, ILLINOIS. ONE POSTER PRESENTATION PROVIDES FURTHER INSIGHTS ON THE MODE OF ACTION OF IO102-IO103, THE COMPANY'S LEAD INVESTIGATIONAL THERAPEUTIC CANCER VACCINE WHICH TARGETS CELLS EXPRESSING IDO1 AND PD-L1, COMPARED TO CONVENTIONAL CHECKPOINT INHIBITORS AND A SECOND SHARES PROMISING UPDATES FOR IO170, WHICH TARGETS TRANSFORMING GROWTH FACTOR BETA (TGF-).

IO BIOTECH PRESENTS NEW DATA AT AACR 2025 SUPPORTING DUAL MECHANISM AND IMMUNE ACTIVATION OF CANCER VACCINES IO102-IO103 AND IO170

 NEW NON-CLINICAL DATA STRENGTHENS EVIDENCE OF CONTRIBUTIONS OF IO102 AND IO103 TO TUMOR GROWTH CONTROL THROUGH TARGET SPECIFIC T-CELL ACTIVATION, OFFERING A DISTINCT AND COMPLEMENTARY APPROACH TO CHECKPOINT INHIBITORS  NEW PRECLINICAL DATA FOR IO170 ADD TO GROWING BODY OF EVIDENCE SUPPORTING THE POTENTIAL OF IMMUNE-MODULATORY THERAPEUTIC CANCER VACCINES TO TREAT A WIDE RANGE OF CANCERS NEW YORK, MARCH 25, 2025 (GLOBE NEWSWIRE) -- IO BIOTECH (NASDAQ: IOBT), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL, IMMUNE-MODULATORY, OFF-THE-SHELF THERAPEUTIC CANCER VACCINES, TODAY ANNOUNCED THAT TWO ABSTRACTS HAVE BEEN ACCEPTED FOR PRESENTATION AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) ANNUAL MEETING 2025 TAKING PLACE APRIL 25-30 IN CHICAGO, ILLINOIS. ONE OF THE POSTERS WILL SHARE INSIGHTS, USING NON-CLINICAL MODELS, RELATED TO IO BIOTECH'S LEAD INVESTIGATIONAL CANDIDATE, IO102-IO103, CURRENTLY BEING EVALUATED IN A PIVOTAL PHASE 3 TRIAL IN ADVANCED MELANOMA.

IO BIOTECH ANNOUNCES ACCEPTANCE OF ABSTRACTS TO BE PRESENTED AT THE 2025 AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) ANNUAL MEETING

BIOPHARMACEUTICAL COMPANY RECOGNIZED FOR INNOVATION IN THE DEVELOPMENT OF IMMUNE-MODULATORY THERAPEUTIC CANCER VACCINES NEW YORK, MARCH 18, 2025 (GLOBE NEWSWIRE) -- IO BIOTECH (NASDAQ: IOBT), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY, HAS BEEN NAMED TO FAST COMPANY'S PRESTIGIOUS LIST OF THE WORLD'S MOST INNOVATIVE COMPANIES OF 2025. FAST COMPANY RECOGNIZES 609 ORGANIZATIONS ACROSS 58 SECTORS AND REGIONS.

IO BIOTECH NAMED AMONG FAST COMPANY'S WORLD'S MOST INNOVATIVE COMPANIES OF 2025

PREPARATIONS FOR SUBMISSION OF A BIOLOGICS LICENSE APPLICATION (BLA) FOR CYLEMBI O  (IMSAPEPIMUT AND ETIMUPEPIMUT, ADJUVANTED) TO FDA BY YEAR END 2025 REMAIN ON TRACK.THE TRIAL COMPLETED ENROLLMENT IN DECEMBER 2023 AHEAD OF PLAN WITH 407 PATIENTS.

IO BIOTECH REPORTS 2024 BUSINESS HIGHLIGHTS

 FINDINGS SUPPORT THE DEVELOPMENT OF A NOVEL PEPTIDE VACCINE TARGETING THE IMMUNOSUPPRESSIVE EFFECTS OF TRANSFORMING GROWTH BETA (TGF-  ) IN SOLID TUMORS NEW YORK, FEB. 23, 2025 (GLOBE NEWSWIRE) -- IO BIOTECH (NASDAQ: IOBT), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL, IMMUNE-MODULATORY, OFF-THE-SHELF THERAPEUTIC CANCER VACCINES, TODAY ANNOUNCED DETAILS OF ITS POSTER PRESENTATION AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR)-IO CONFERENCE TAKING PLACE FEBRUARY 23-26, 2025, IN LOS ANGELES, CALIFORNIA. POSTER PRESENTATION DETAILS TITLE: A TGF--DIRECTED PEPTIDE VACCINE INDUCES T CELL ACTIVATION & DRIVES ANTI-TUMOR ACTIVITY BY MODULATING THE ARCHITECTURE OF THE TUMOR MICROENVIRONMENT POSTER NUMBER: B117 PRESENTER: MATTEO BOCCI, PHD, SENIOR SCIENTIST DATE AND TIME: TUESDAY, FEBRUARY 25, 2025, 1:45-4:00 PM PST LOCATION: JW MARRIOTT LOS ANGELES, PLATINUM BALLROOM A-E TRANSFORMING GROWTH FACTOR BETA (TGF-) IS A KEY IMMUNE-SUPPRESSIVE FACTOR IN THE TUMOR MICROENVIRONMENT (TME) OF MOST SOLID TUMORS, OFTEN LIMITING THE EFFICACY OF VARIOUS IMMUNE-ONCOLOGY THERAPIES.

IO BIOTECH ANNOUNCES NEW PRECLINICAL DATA FOR ADDITIONAL PIPELINE CANDIDATE PRESENTED AT THE AACR-IO CONFERENCE

PRESENTATION WILL INCLUDE AN UPDATE ON THE DEVELOPMENT AND LAUNCH PREPARATIONS OF CYLEMBIO (IMSAPEPIMUT AND ETIMUPEPIMUT, ADJUVANTED) NEW YORK, FEB. 20, 2025 (GLOBE NEWSWIRE) -- IO BIOTECH (NASDAQ: IOBT), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL, IMMUNE-MODULATORY, OFF-THE-SHELF THERAPEUTIC CANCER VACCINES, TODAY ANNOUNCED THAT MAI-BRITT ZOCCA, PHD, PRESIDENT AND CEO, WILL PRESENT A COMPANY OVERVIEW AT THE 45TH ANNUAL COWEN HEALTH CARE CONFERENCE TO BE HELD MARCH 3-5, 2025 IN BOSTON, MA. DR. ZOCCA, JOINED BY AMY SULLIVAN, CFO, AND QASIM AHMAD, MD, CMO, WILL ALSO BE HOSTING ONE-ON-ONE INVESTOR MEETINGS DURING THE CONFERENCE.

IO BIOTECH TO PRESENT AT THE 45TH ANNUAL COWEN HEALTH CARE CONFERENCE

COPENHAGEN, DENMARK AND NEW YORK, DEC. 20, 2024 (GLOBE NEWSWIRE) -- IO BIOTECH (NASDAQ: IOBT), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL, IMMUNE-MODULATING, OFF-THE-SHELF THERAPEUTIC CANCER VACCINES TODAY ANNOUNCED THAT IT HAS ENTERED INTO A LOAN FACILITY OF UP TO 57.5 MILLION FROM THE EUROPEAN INVESTMENT BANK (EIB), THE LONG-TERM LENDING INSTITUTION OF THE EUROPEAN UNION OWNED BY ITS MEMBER STATES. THE DEBT FACILITY INCLUDES THREE COMMITTED TRANCHES TOTALING UP TO 37.5 MILLION, WHICH WILL BECOME AVAILABLE IF THE COMPANY SATISFIES CERTAIN CONDITIONS, AND ONE UNCOMMITTED ACCORDION TRANCHE OF 20 MILLION. THE COMPANY EXPECTS THE FIRST TWO TRANCHES TO BE AVAILABLE FOR DISBURSEMENT IN THE FIRST QUARTER OF 2025.

IO Biotech, Inc.

IOBT

Price

Financials Overview

Financial Reports

No items found.

Press Releases

IO Biotech, Inc.

IOBT.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

IOBT